Shining a Light on HER2-Low and HER2-Ultralow Metastatic Breast Cancer: A Pathologist’s Guide to Bridging the Diagnostic Gaps

Learn to score HER2 levels via immunohistochemistry in both routine and complex breast cancer cases, identify patients who may benefit from HER2-targeted therapy, and select novel therapies for treatment of HER2-low or HER2-ultralow metastatic breast cancer by attending a live, on-demand webcast and reviewing an expert-written commentary and downloadable slides.

Share

Program Content

Events

Activities

Essentials for HER2-Low/Ultralow Metastatic Breast Cancer
Shining a Light on HER2-Low and HER2-Ultralow Metastatic Breast Cancer: A Pathologist’s Guide to Bridging the Diagnostic Gaps
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 21, 2025

Expires: September 20, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.